Loading data for TLSA — first visit, this takes a few seconds.
Tiziana Life Sciences Ltd (TLSA) : cours, analyse et données
Valeur intrinsèque
Prévisions des analystes
Prévisions boursières →Derniers résultats
| Signalé | Écart estimé | Changement d’une année sur l’autre | |
|---|---|---|---|
| Chiffre d’affaires | — | n/a | n/a |
| EPS | -$0,06 | n/a | n/a |
Métriques
- Cours acheteur
- 0.97
- Résultat net (ttm)
- -18.4M
- 0.45
- -0.16
- n/a
- -4.51
- P/B (ttm)
- n/a
- P/S (ttm)
- n/a
- Date des résultats
- n/a
- Cours vendeur
- 0.99
- Volume
- 272,913
- Volume moy. (20D)
- 576,601
- Ouverture
- 0.98
- Clôture précédente
- 0.96
- Fourchette du jour
- 0.93 - 0.99
- Intervalle de 52 semaines
- 0.87 - 2.35
- Analyste
- n/a
- Objectif de prix
- n/a
- Dividendes
- n/a
- Date ex-dividende
- n/a
À propos de Tiziana Life Sciences Ltd
Voir le profil →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Industrie Biotechnology
Secteur Healthcare
Date d’introduction Nov 20, 2018
Employés 10
Bourse NasdaqCM
Symbole boursier TLSA
Site web https://www.tizianalifesciences.com